Reuters logo
BRIEF-Selecta presents phase 1 clinical data for lead product candidate, SEL-212
December 7, 2016 / 1:35 PM / in 10 months

BRIEF-Selecta presents phase 1 clinical data for lead product candidate, SEL-212

Dec 7 (Reuters) - Selecta Biosciences Inc

* Selecta presents phase 1 clinical data for lead product candidate, SEL-212, in patients with hyperuricemia at 11th annual IMVAC summit

* Selecta Biosciences Inc says SEL-212 was generally well tolerated at clinically active doses

* Selecta Biosciences Inc says data show substantial and sustained reduction of serum uric acid levels for 30 days or longer after single dose Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below